THIS is the Only Indian state that Made Into New York Time's List of '52 Places To Visit in 2016'

The state has been added to the list because it provides "new gateways to India's cultural core."

Most Popular

New York Times has released it's list of '52 Place sTo Visit in 2016' and Tamil Nadu is the only Indian state to have made into the list!

Advertisement - Continue Reading Below

According to NYT, Tamil Nadu offers a new look into the rich culture and heritage of the country, and while northern states like Rajasthan and Gujarat are mostly popular with tourists, Tamil Nadu has a lot to offer to.

North India, with its famous Moghul era palaces and forts, might be the country's most popular tourist destination, but Tamil Nadu in the south has an equally rich and undiscovered history.

Mexico City, Bordeaux (France) and Malta have been named the top 3 places to visit.

What do you think?

Life
Share
Francia Raisa Shows Her Scars for the First Time Since Donating a Kidney to Selena Gomez
"Happy to be back," she wrote on Instagram.
Life
Share
If Music Gives You Goosebumps, Your Brain Might Be Special
Science finally has an explanation for that tingly feeling.
Life
Share
I Lost 20 Lbs On The Anti-Inflammatory Diet—And Fixed My Skin Forever
One month in, my life changed completely.
Life
Share
Why Some People Aren't So Happy About the New Royal Baby
Not everyone is excited about Will and Kate's expanding family.
Life
Share
Do-Nut Freak Out Over These Sweet New Disney Treats
Mickey! Mouse! Donuts!
Life
Share
Donald Trump and First Lady Melania Had Yet Another Very Awkward Handshake Moment
Did he just... push her?
Life
Share
Netflix Users, Beware of This Email Scam That Looks So Real It's Scary
Be sure to warn your friends!
Life
Share
Incredible Body Transformation Shows What Happens When You Ditch Cardio and Dieting
The difference is astounding.
Life
Share
What Your Go-To Sexy Bra Says About Who You Attract
The truth is very revealing.
Life
Share
No One *Really* Knows What Happens When Pregnant Women Drink Just a Little
Evidence of adverse effects is surprisingly sparse.